URGN
UroGen Pharma Ltd. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow -26.3% ·
net new positions +15.4%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 20.29K | $750,361 | n/a | n/a |
| Q2 2026 | 76 | +11 | 16.33M | $600.16M | +14 | −3 |
| Q1 2026 | 68 | -2 | 16.64M | $299.41M | +7 | −9 |
| Q4 2025 | 71 | 0 | 16.74M | $392.08M | n/a | n/a |
| Q3 2025 | 18 | -2 | 12.72M | $253.85M | n/a | −2 |
| Q2 2025 | 17 | +1 | 7.27M | $99.60M | +1 | n/a |
| Q1 2025 | 13 | 0 | 4.33M | $47.90M | n/a | n/a |
| Q4 2024 | 13 | +2 | 6.43M | $68.46M | +2 | n/a |
| Q3 2024 | 10 | -2 | 7.92M | $100.53M | n/a | −2 |
| Q2 2024 | 12 | n/a | 7.91M | $132.72M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 2.93M | -21.6% | $31.18M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 808.05K | n/a | $8.61M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 645.78K | -56.9% | $6.88M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 461.90K | +1.4% | $4.92M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | T. Rowe Price ✦ | 393.98K | +2968.7% | $4.20M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 317.11K | -79.0% | $3.38M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 228.78K | -5.5% | $2.44M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 146.95K | +7.0% | $1.57M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | ARK Investment Management ✦ | 140.15K | +15.2% | $1.49M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 138.20K | New | $1.47M | 0.0% | New | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 136.49K | New | $1.45M | 0.0% | New | 1 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 56.90K | -34.6% | $605,932 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 25.49K | -78.4% | $271,458 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $1.47M | 0.0% |
| Marshall Wace | $1.45M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 171 holders, 46.40M shares, $801.72M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.20K sh · $80,791
Officer · 1.52K sh · $64,618
Officer · 871 sh · $37,383
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology